

Finasteride (1%) Formulation

Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
Date of first issue: 2015/01/26

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Finasteride (1%) Formulation

Supplier's company name, address and phone number

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

E-mail address : EHSSTEWARD@organon.com

Emergency telephone number : 215-631-6999

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION**GHS classification of chemical product**

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Testis)

Long-term (chronic) aquatic hazard : Category 3

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.
H373 May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

SAFETY DATA SHEET



Finasteride (1%) Formulation



Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
Date of first issue: 2015/01/26

Response:

P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and out- : Dust contact with the eyes can lead to mechanical irritation.
lines of the emergency as- : Contact with dust can cause mechanical irritation or drying of
sumed : the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Cellulose	9004-34-6	$\geq 1 - < 10$	
Starch	9005-25-8	$\geq 1 - < 10$	8-98
Finasteride	98319-26-7	$\geq 1 - < 2.5$	
Titanium dioxide	13463-67-7	$\geq 0.1 - < 1$	1-558, 5-5225
Diiron trioxide	1309-37-1	$\geq 0.1 - < 1$	1-357, 5-5188
Iron oxide	1332-37-2	$\geq 0.1 - < 1$	1-357
Sodium bis(2-ethylhexyl)sulfosuccinate	577-11-7	$\geq 0.1 - < 0.25$	2-1623, 2-1620

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

SAFETY DATA SHEET



Finasteride (1%) Formulation



Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
Date of first issue: 2015/01/26

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE
Handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Avoidance of contact | : | Oxidizing agents |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

Storage

- | | | |
|-----------------------------|---|--|
| Conditions for safe storage | : | Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations. |
|-----------------------------|---|--|

SAFETY DATA SHEET



Finasteride (1%) Formulation



Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
 Date of first issue: 2015/01/26

Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH
Finasteride	98319-26-7	TWA	0.5 µg/m ³ (OEB 5)	Internal
		Wipe limit	5 µg/100 cm ²	Internal
Titanium dioxide	13463-67-7	OEL-M (Respirable dust)	1 mg/m ³ (Titanium)	JP OEL JSOH
	Further information: Class 2 Dust			
		OEL-M (Total dust)	4 mg/m ³ (Titanium)	JP OEL JSOH
	Further information: Class 2 Dust			
		TWA	10 mg/m ³ (Titanium dioxide)	ACGIH
Iron oxide	1332-37-2	OEL-M (Respirable dust)	1 mg/m ³ (Iron)	JP OEL JSOH
	Further information: Class 2 Dust			
		OEL-M (Total dust)	4 mg/m ³ (Iron)	JP OEL JSOH
	Further information: Class 2 Dust			
Diiron trioxide	1309-37-1	OEL-M (Respirable dust)	1 mg/m ³ (Iron)	JP OEL JSOH
	Further information: Class 2 Dust			
		OEL-M (Total dust)	4 mg/m ³ (Iron)	JP OEL JSOH
	Further information: Class 2 Dust			
		TWA (Respirable particulate matter)	5 mg/m ³	ACGIH

These substance(s) are inextricably bound in the product and therefore do not contribute to a dust inhalation hazard.

Titanium dioxide

Engineering measures : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
 All engineering controls should be implemented by facility

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

design and operated in accordance with GMP principles to protect products, workers, and the environment.
No open handling permitted.
Totally enclosed processes and materials transport systems are required.
Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	:	powder
Colour	:	tan
Odour	:	odourless
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Boiling point, initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Lower explosion limit and upper explosion limit / flammability limit	:	
Upper explosion limit / Upper flammability limit	:	No data available

SAFETY DATA SHEET



Finasteride (1%) Formulation



Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
Date of first issue: 2015/01/26

Lower explosion limit / Lower flammability limit : No data available

Flash point : Not applicable

Decomposition temperature : No data available

pH : No data available

Evaporation rate : Not applicable

Auto-ignition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : log Pow: 3.5
pH: 7
Active ingredient

Vapour pressure : Not applicable

Density and / or relative density
Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics
Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure :
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Finasteride:

Acute oral toxicity : LD50 (Rat): 373 - 828 mg/kg

LD50 (Mouse): 486 mg/kg

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Diiron trioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Iron oxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Remarks: Based on data from similar materials

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

Sodium bis(2-ethylhexyl)sulfosuccinate:

Acute oral toxicity : LD50 (Rat): 3,080 mg/kg
Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Finasteride:**

Species : Rabbit
Result : No skin irritation

Titanium dioxide:

Species : Rabbit
Result : No skin irritation

Diiron trioxide:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Iron oxide:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Sodium bis(2-ethylhexyl)sulfosuccinate:

Species : Rabbit
Method : OECD Test Guideline 404
Result : Skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Starch:**

Species : Rabbit
Result : No eye irritation

Finasteride:

Species : Rabbit
Remarks : slight irritation

Finasteride (1%) Formulation

Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
Date of first issue: 2015/01/26

Titanium dioxide:

Species : Rabbit
Result : No eye irritation

Diiron trioxide:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405

Iron oxide:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405
Remarks : Based on data from similar materials

Sodium bis(2-ethylhexyl)sulfosuccinate:

Species : Rabbit
Result : Irreversible effects on the eye
Method : OECD Test Guideline 405

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Starch:**

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse
Result : negative

Diiron trioxide:

Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Iron oxide:

Exposure routes : Skin contact
Species : Guinea pig

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

Result : negative
 Remarks : Based on data from similar materials

Sodium bis(2-ethylhexyl)sulfosuccinate:

Test Type : Human repeat insult patch test (HRIPT)
 Exposure routes : Skin contact
 Species : Humans
 Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Test Type: In vitro mammalian cell gene mutation test
 Result: negative
 Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Finasteride:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
 Result: positive
 Test Type: In vitro mammalian cell gene mutation test
 Result: negative
 Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Test Type: Alkaline elution assay
 Result: negative
 Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
 Application Route: Oral
 Result: negative

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Diiron trioxide:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative

Iron oxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Sodium bis(2-ethylhexyl)sulfosuccinate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: equivocal

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Finasteride:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
: 160 mg/kg body weight
Result : negative
Target Organs : Testes
Remarks : Benign tumor(s)

Species : Mouse
Application Route : Ingestion
Exposure time : 19 month(s)

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

Result : negative
 Target Organs : Testes
 Remarks : Benign tumor(s)

Titanium dioxide:

Species : Rat
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 2 Years
 Method : OECD Test Guideline 453
 Result : positive
 Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

Diiron trioxide:

Species : Rat
 Application Route : Intraperitoneal injection
 Exposure time : 790 - 914 days
 Result : negative

Iron oxide:

Species : Rat
 Application Route : Intraperitoneal injection
 Exposure time : 790 - 914 days
 Result : negative
 Remarks : Based on data from similar materials

Reproductive toxicity

May damage the unborn child.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Result: negative

Finasteride:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rabbit
 Application Route: Oral
 Fertility: NOAEL: 80 mg/kg body weight
 Result: No effects on fertility

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Fertility: LOAEL: 80 mg/kg body weight
 Result: positive
 Remarks: There is no evidence that these findings are relevant to humans.

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Ingestion
 Developmental Toxicity: LOAEL: 0.003 mg/kg body weight
 Result: Teratogenic effects, Embryotoxic effects.

Test Type: Embryo-foetal development
 Species: Monkey
 Application Route: Ingestion
 Developmental Toxicity: LOAEL: 2 mg/kg body weight
 Result: Teratogenic effects

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Sodium bis(2-ethylhexyl)sulfosuccinate:

Effects on fertility : Test Type: Three-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Ingestion
 Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.

Components:**Finasteride:**

Exposure routes : Ingestion
 Target Organs : Testis
 Assessment : Causes damage to organs through prolonged or repeated exposure.

Iron oxide:

Exposure routes : inhalation (dust/mist/fume)
 Assessment : No significant health effects observed in animals at concentrations of 0.2 mg/l/6h/d or less.

Finasteride (1%) Formulation

Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
Date of first issue: 2015/01/26

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
NOAEL : $\geq 9,000$ mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Starch:

Species : Rat
NOAEL : $\geq 2,000$ mg/kg
Application Route : Skin contact
Exposure time : 28 Days
Method : OECD Test Guideline 410

Finasteride:

Species : Rat
NOAEL : 20 mg/kg
LOAEL : 40 mg/kg
Application Route : Oral
Exposure time : 1 yr
Target Organs : Testis

Species : Dog
NOAEL : 45 mg/kg
Application Route : Oral
Exposure time : 1 yr
Target Organs : Testis

Titanium dioxide:

Species : Rat
NOAEL : 24,000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days

Species : Rat
NOAEL : 10 mg/m³
Application Route : inhalation (dust/mist/fume)
Exposure time : 2 yr

Iron oxide:

Species : Rat
NOAEL : 4.7 mg/m³
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 Days
Method : OECD Test Guideline 413
Remarks : Based on data from similar materials

Sodium bis(2-ethylhexyl)sulfosuccinate:

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

Species	:	Rat
NOAEL	:	750 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Finasteride:**

Ingestion	:	Symptoms: breast tenderness, breast enlargement, impotence, lip swelling, skin rash
-----------	---	---

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	:	LC50 (<i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	--

Finasteride:

Toxicity to fish	:	LC50 (<i>Oncorhynchus mykiss</i> (rainbow trout)): 20.4 mg/l Exposure time: 96 h Method: FDA 4.11
------------------	---	--

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (<i>Daphnia magna</i> (Water flea)): 17.8 mg/l Exposure time: 48 h Method: FDA 4.08
---	---	---

Toxicity to algae/aquatic plants	:	NOEC (<i>Pseudokirchneriella subcapitata</i> (green algae)): 49 mg/l Exposure time: 14 h Method: FDA 4.01
----------------------------------	---	--

Toxicity to fish (Chronic toxicity)	:	NOEC (<i>Oryzias latipes</i> (Orange-red killifish)): 0.05 mg/l Exposure time: 105 d
-------------------------------------	---	--

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (<i>Daphnia magna</i> (Water flea)): 0.12 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
--	---	--

M-Factor (Chronic aquatic toxicity)	:	1
-------------------------------------	---	---

Titanium dioxide:

Toxicity to fish	:	LC50 (<i>Oncorhynchus mykiss</i> (rainbow trout)): > 100 mg/l
------------------	---	--

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Diiron trioxide:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 50,000 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to microorganisms : EC50: > 10,000 mg/l
Exposure time: 3 h

Iron oxide:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10,000 mg/l
Exposure time: 96 h
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50: >= 10,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209
Remarks: Based on data from similar materials

Sodium bis(2-ethylhexyl)sulfosuccinate:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): 49 mg/l
Exposure time: 96 h
Method: Directive 67/548/EEC, Annex V, C.1.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 6.6 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 82.5 mg/l
Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 22 mg/l
Exposure time: 72 h

Toxicity to daphnia and other : EC10 (Daphnia magna (Water flea)): 9 mg/l

SAFETY DATA SHEET



Finasteride (1%) Formulation

Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
Date of first issue: 2015/01/26

aquatic invertebrates (Chronic toxicity) Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Pseudomonas putida): 164 mg/l
Exposure time: 16 h

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Finasteride:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 0 %
Exposure time: 7 d
Method: FDA 3.11

Stability in water : Hydrolysis: 0 %(5 d)
Method: FDA 3.09

Sodium bis(2-ethylhexyl)sulfosuccinate:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 91.2 %
Exposure time: 28 d

Bioaccumulative potential

Components:

Finasteride:

Partition coefficient: n-octanol/water : log Pow: 3.57

Sodium bis(2-ethylhexyl)sulfosuccinate:

Partition coefficient: n-octanol/water : log Pow: 1.998
Remarks: Calculation

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

SAFETY DATA SHEET



Finasteride (1%) Formulation



Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
Date of first issue: 2015/01/26

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

15. REGULATORY INFORMATION

Related Regulations

Fire Service Law

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Priority Assessment Chemical Substance

Chemical name	Number
Sodium 1,4-bis[(2-ethylhexyl)oxy]-1,4-dioxobutane-2-sulfonate	213

Industrial Safety and Health Law

Harmful Substances Prohibited from Manufacture

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Article 57-2 (Enforcement Order Table 9)

Chemical name	Number	Concentration (%)
---------------	--------	-------------------

SAFETY DATA SHEET



Finasteride (1%) Formulation



Version 10.1 Revision Date: 2020/10/10 SDS Number: 49649-00017 Date of last issue: 2020/03/23
Date of first issue: 2015/01/26

Titanium(IV) oxide	191	$\geq 0.1 - < 1$
Iron oxide	192	$\geq 1 - < 10$

Substances Subject to be Indicated Names

Article 57 (Enforcement Order Article 18)

Chemical name	Number
Iron oxide	192

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Not regulated as a dangerous good

Aviation Law

Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
 JP OEL JSOH : Japan. The Japan Society for Occupational Health. Recommendation of Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average
 JP OEL JSOH / OEL-M : Occupational Exposure Limit-Mean

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods;

SAFETY DATA SHEET



Finasteride (1%) Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 2020/03/23
10.1	2020/10/10	49649-00017	Date of first issue: 2015/01/26

vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN